Showing 2601-2610 of 4063 results for "".
- Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022https://modernod.com/news/opthea-data-for-opt-302-in-patients-with-polypoidal-choroidal-vasculopathy-pcv-presented-at-angiogenesis-2022/2480640/Opthea announced data was presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference. The presentation, entitled “OPT-302 Combination Therapy with Ranibizumab for Treatment of Polypoidal Choroidal Vasculopathy,&r
- My Vision Show 2022 to Preview "The Optiverse"https://modernod.com/news/my-vision-show-2022-to-preview-the-optiverse/2480615/My Vision Show, an optical virtual events production and media company, announced that My Vision Show Spring 2022,
- GlobalData: Glaucoma Market to Grow to $3.5 Billion by 2030, Driven by Launch of New Pipeline Productshttps://modernod.com/news/globaldata-glaucoma-market-to-grow-to-35-billion-by-2030-driven-by-launch-of-new-pipeline-products/2480609/Steady growth is expected for the glaucoma market across the seven major markets* from $2.8 billion in 2020 to $3.5 billion in 2030, at a compound annual growth rate (CAGR) of 2.0%, according to GlobalData. According to the leading data and analytics company’s latest re
- 2022 President Robert E. Wiggins Jr., MD, MPH Takes the Academy’s Reinshttps://modernod.com/news/2022-president-robert-e-wiggins-jr-md-mph-takes-the-academys-reins/2480585/Medicine is a constantly developing industry—just ask 2022 Academy President Robert E. Wiggins Jr., MD, MPH. When his practice was acquired in the 1990s, Dr. Wiggins returned to school and obtained a masters degree in health care administration, turning Asheville Eye Associa
- More than 240 Exhibitors Commit to Vision Expo East 2022, Taking Place In-Person from March 31–April 3 at the Javits Centerhttps://modernod.com/news/more-than-240-exhibitors-commit-to-vision-expo-east-2022-taking-place-in-person-from-march-31-april-3-at-the-javits-center/2480582/The organizers of Vision Expo, The Vision Council and RX, share that more than 240 exhibitors have committed to Vision Expo East to-date. Vision Expo East 2022 will take place from March 31–April 3 at the Jacob Javits Center in New York City. &l
- Glaukos’ iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Studyhttps://modernod.com/news/glaukos-idose-tr-demonstrates-sustained-iop-reduction-and-favorable-safety-profile-over-36-months-in-phase-2b-study/2480567/Glaukos announced that its iDose TR sustained-release travoprost implant continued to provide sustained substantial reductions in IOP in a 36-month analysis of the phase 2b clinical trial conducted under a U.S. investigational new drug (IND) protocol. <
- EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievementshttps://modernod.com/news/eyepoint-pharmaceuticals-announces-2022-clinical-plans-and-highlights-recent-corporate-and-clinical-achievements/2480554/EyePoint Pharmaceuticals announced its 2022 clinical pipeline plans and highlighted recent corporate achievements driven by its lead pipeline candidate, EYP-1901, a potential 6-month intravitreal treatment targeting wet age-related macular degeneration (AMD).
- Nicox European Patent Seals Zerviate Major Market Coverage to 2030https://modernod.com/news/nicox-european-patent-seals-zerviate-major-market-coverage-to-2030/2480545/Nicox announced that patent EP2408453, covering the company’s product Zerviate (cetirizine ophthalmic solution) 0.24%, has been issued by the European Patent Office (EPO). The patent covers the formulation of Zerviate which is commercialized in the US by exclusive US licensee
- Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-positive-safety-results-from-oasis-phase-12a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2480529/Clearside Biomedical announced positive safety results from OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector. OASIS is evaluating CLS-AX for the treatment o
- Nicox’s Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path Forward in Dry Eye Diseasehttps://modernod.com/news/nicoxs-positive-post-hoc-results-from-ncx-4251-phase-2b-mississippi-trial-suggest-path-forward-in-dry-eye-disease/2480480/Nicox SA announced positive post hoc results from its Mississippi Phase 2b clinical trial suggesting that once-daily dosed NCX 4251, fluticasone propionate ophth